Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Tomoko Henzan"'
Autor:
Kazuhiro Shirozu, Naoyuki Fujimura, Yuji Karashima, Mizuko Ikeda, Hidehisa Kitada, Yasuhiro Okabe, Kei Kurihara, Tomoko Henzan, Sumio Hoka
Publikováno v:
BMC Anesthesiology, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background ABO-incompatible living-donor kidney transplantation (LDKT) requires immunotherapy and plasma exchange therapy (PEX). PEX with albumin replacement fluid reportedly decreases fibrinogen levels. However, no reports have described th
Externí odkaz:
https://doaj.org/article/3966d4f90d0a499591878e459829b377
Autor:
Keiko Fujino, Kyoko Yamaguchi, Mari Enomoto, Taeko Hotta, Tomoko Henzan, Yuya Kunisaki, Koichi Akashi
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 69:20-26
Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan
Autor:
Tomoyasu Jo, Satoshi Yoshihara, Yoshiki Okuyama, Keiko Fujii, Tomoko Henzan, Kaoru Kahata, Rie Yamazaki, Wataru Takeda, Yoshihiro Umezawa, Kentaro Fukushima, Takashi Ashida, Minami Yamada‐Fujiwara, Ryo Hanajiri, Noboru Yonetani, Yuma Tada, Yuji Shimura, Hidekazu Nishikii, Norio Shiba, Naoya Mimura, Jun Ando, Takayuki Sato, Yasuhiro Nakashima, Junko Ikemoto, Keita Iwaki, Shin‐ichiro Fujiwara, Masaki Ri, Tokiko Nagamura‐Inoue, Ryuji Tanosaki, Yasuyuki Arai
Publikováno v:
British Journal of Haematology.
For successful chimeric antigen receptor T (CAR-T) cell therapy, CAR-T cells must be manufactured without failure caused by suboptimal expansion. In order to determine risk factors for CAR-T cell manufacturing failure, we performed a nationwide cohor
Autor:
Yasuhiro Nakashima, Takuji Yamauchi, Ikumi Yamanaka, Yuya Kunisaki, Yoshihiro Ogawa, Koichi Akashi, Teppei Sakoda, Tomoko Henzan, Takahiro Maeda, Koji Kato, Toshihiro Miyamoto, Hiroaki Ono, Hiroyuki Mishima, Yuhki Koga, Shinichi Mizuno, Shouichi Ohga, Kyoko Miyamoto
Publikováno v:
International Journal of Hematology. 114:449-458
Collection of CD3+ lymphocytes via lymphapheresis is essential for manufacturing autologous chimeric antigen receptor (CAR) T cells. Optimization of timing and procedures for lymphapheresis for each patient is critical because patients often have pro
Autor:
Hiromi Iwasaki, Kenjiro Kamezaki, Takahiro Maeda, Teppei Sakoda, Tomoko Henzan, Yuya Kunisaki, Koichi Akashi, Toshihiro Miyamoto, Takanori Teshima, Takeshi Sugio, Takahiro Shima
Publikováno v:
Journal of Clinical Apheresis. 36:687-696
BACKGROUND Peripheral blood stem cell (PBSC) transplantation is a key treatment option for hematological diseases and is widely performed in clinical practice. Platelet loss is one of the major complications of PBSC apheresis, and platelet-rich plasm
Autor:
Kazuo Kawahara, Katsunori Ohyama, Tomoko Henzan, Makiko Sugawa, Kazuhiro Nagai, Kazunori Nakajima, Kimitaka Sagawa
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 67:9-20
Autor:
Tomoko, Henzan
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 62(7)
In the clinical practice of hematology, the awareness of team-based medical care has become predominant, and effective coordination with other medical staff members and different departments is essential. The transfusion department where I am employe
Autor:
Tomoko Henzan, Dongchon Kang, Kanae Aoki, Kyoko Yamaguchi, Mari Enomoto, Kenjiro Kamezaki, Taeko Hotta, Ayaka Matsuo
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 64:602-607
Autor:
Katsuto Takenaka, Takahiro Maeda, Daisuke Ishihara, Koji Kato, Fumiaki Jinnnouchi, Takumi Matsushima, Tomoko Henzan, Goichi Yoshimoto, Akihiko Numata, Yasuo Mori, Toshihiro Miyamoto, Koichi Akashi, Mariko Minami
Publikováno v:
Bone Marrow Transplantation. 54:1374-1376
Autor:
Koichi Akashi, Toshihiro Miyamoto, Takahiro Maeda, Teppei Sakoda, Takahiro Shima, Tomoko Henzan, Yuya Kunisaki
Publikováno v:
Blood. 136:29-30
Peripheral blood stem cell (PBSC) transplantation is a key treatment option for hematological diseases and widely performed in clinical practice. Platelet loss is the major complication of PBSC apheresis, and platelet-rich plasma (PRP) return is reco